aspirin has been researched along with Arteriosclerosis Obliterans in 19 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " It cannot, however, be concluded from this study that 75 mg dipyridamole in combination with 100 mg ASA tid is more effective in preventing reocclusion after PTA than in combination with 330 mg ASA tid." | 2.67 | Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. ( Deichsel, G; Heiss, HW; Just, H; Middleton, D, 1990) |
| "The effect of 7-mono-hydroxyethylrutoside and its combination with acetylsalicylic acid was evaluated in a controlled clinical trial, performed in 105 patients with obliterative atherosclerosis of the lower limbs, and using non-invasive measurement of peripheral haemodynamic parameters--blood flow during reactive hyperaemia and ankle systolic blood pressure." | 2.66 | The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis. ( Linhart, J; Oliva, I; Prerovský, I; Roztocil, K, 1989) |
| " Proved herein is the necessity of long-term administration of antiplatelet drugs in order to prevent vascular complications on the part of the heart, brain, and peripheral arteries, with a description of the drugs most commonly used for these purposes." | 1.36 | [Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries]. ( Dzhalilova, NS; Kuznetsov, MR; Sizarev, AV; Tepliakov, SA; Tugdumov, BV, 2010) |
| "Thirty-nine patients with deep vein thrombosis, 28 with arteriosclerosis obliterans, and 10 with pulmonary embolism were the subjects of this study." | 1.31 | Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy. ( Morimoto, Y; Mukai, T; Okada, M; Sugimoto, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (47.37) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, JY | 1 |
| Shi, WH | 1 |
| He, J | 1 |
| Zhu, L | 1 |
| Wang, TP | 1 |
| Yu, B | 1 |
| Kuznetsov, MR | 1 |
| Tepliakov, SA | 1 |
| Sizarev, AV | 1 |
| Tugdumov, BV | 1 |
| Dzhalilova, NS | 1 |
| Tryniszewski, W | 1 |
| Nowak, D | 1 |
| Brocki, M | 1 |
| Maziarz, Z | 1 |
| Rysz, J | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Leo, W | 1 |
| Westrych, R | 1 |
| Bissinger, A | 1 |
| Okraszewski, J | 1 |
| Baj, Z | 1 |
| Grodzińska, L | 1 |
| Basista, M | 1 |
| Kedzior, A | 1 |
| Korbut, R | 1 |
| Kostka-Trabka, E | 1 |
| Gryglewski, R | 1 |
| Terano, T | 1 |
| Hirai, A | 1 |
| Shiina, T | 1 |
| Tamura, Y | 1 |
| Saitoh, Y | 1 |
| Salat, A | 1 |
| Boehm, D | 1 |
| Pulaki, S | 1 |
| Murabito, M | 1 |
| Berlakovich, G | 1 |
| Kretschmer, G | 1 |
| Mueller, MR | 1 |
| Morimoto, Y | 1 |
| Sugimoto, T | 1 |
| Okada, M | 1 |
| Mukai, T | 1 |
| Zabel Langhennig, R | 1 |
| Heiss, HW | 1 |
| Just, H | 1 |
| Middleton, D | 1 |
| Deichsel, G | 1 |
| Berge, PG | 1 |
| Höpp, HW | 1 |
| Roztocil, K | 1 |
| Oliva, I | 1 |
| Prerovský, I | 1 |
| Linhart, J | 1 |
| Strano, A | 2 |
| Davì, G | 2 |
| Cannizzaro, S | 1 |
| Giubilato, A | 1 |
| Pinto, A | 1 |
| Palumbo, MG | 1 |
| Gallo, V | 1 |
| Mazza, A | 1 |
| Rosenthal, D | 1 |
| Mittenthal, MJ | 1 |
| Ruben, DM | 1 |
| Jones, DH | 1 |
| Estes, JW | 1 |
| Stanton, PE | 1 |
| Lamis, PA | 1 |
| Abrahamsen, AF | 1 |
| Eika, C | 1 |
| Godal, HC | 1 |
| Lorentsen, E | 1 |
| Zeitler, E | 1 |
| Cavalieri, U | 1 |
| Quadri, A | 1 |
| Tammaro, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Asymptomatic Cuff Tears: A Model for Pain Development - Part B[NCT00923858] | 495 participants (Actual) | Observational | 2005-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aspirin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Mechanism of anti-proliferative action of eicosapentaenoic acid (EPA) in vascular cell growth: its effect on signal transduction system.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arterioscl | 1997 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
8 trials available for aspirin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arteriosclerosis Obliterans; Aspirin; Cathe | 2008 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
[Effect of the acetylosalicyd acid (ASA) and ticlopidine therapy on clinical condition and parameters of blood platelets in patients with peripheral arterial occlusive disease (PAOD)].
Topics: Adult; Aged; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Exercise Test; Female; Humans; M | 2007 |
Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriosclerosis Obliterans; Aspirin; Dipyrida | 1990 |
[Prevention of obliterating arterial diseases with acetylsalicylic acid].
Topics: Arteriosclerosis Obliterans; Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction | 1990 |
The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis.
Topics: Adult; Analgesics; Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Clinical Trials as Topic; D | 1989 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
Effect of acetylsalicylic acid and dipyridamole on platelet survival and aggregation in patients with atherosclerosis obliterans.
Topics: Aged; Arteriosclerosis Obliterans; Aspirin; Blood Cell Count; Blood Platelets; Cell Survival; Clinic | 1974 |
10 other studies available for aspirin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries].
Topics: Arteriosclerosis Obliterans; Aspirin; Chronic Disease; Fibrinolytic Agents; Hemorrhage; Humans; Leg; | 2010 |
Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study.
Topics: Analysis of Variance; Arteriosclerosis Obliterans; Aspirin; Blood Flow Velocity; Exercise; Female; H | 2010 |
Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans.
Topics: Arteriosclerosis Obliterans; Aspirin; Epoprostenol; Fibrinolysis; Humans; Leg; Platelet Aggregation; | 1983 |
Possibility of checking compliance and efficacy of antiaggregatory treatment following femoro-popliteal vein bypass surgery.
Topics: Anastomosis, Surgical; Arteriosclerosis Obliterans; Aspirin; Blood Coagulation; Female; Femoral Vein | 1998 |
Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Blood Platelet | 2000 |
[Inhibitors of platelet aggregation in the therapy of arteriosclerosis obliterans].
Topics: Arteriosclerosis Obliterans; Aspirin; Diabetic Angiopathies; Dipyridamole; Humans; Platelet Aggregat | 1979 |
Dipyridamole and aspirin in arteriosclerosis obliterans of the lower limbs.
Topics: Adenosine Diphosphate; Adult; Arteriosclerosis Obliterans; Aspirin; Dipyridamole; Drug Therapy, Comb | 1985 |
The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Arteriovenous Shunt, Surgical; Aspirin; | 1987 |
[The percutaneous recanalization of arterial obliterations with Dotter's catheter (Dotter's technic)].
Topics: Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Catheterization; Collateral Circulation; Femor | 1972 |
[Preliminary clinical uses of aspirin as an anticoagu.ant. (Preliminary note)].
Topics: Aged; Arteriosclerosis Obliterans; Aspirin; Female; Humans; Intracranial Arteriosclerosis; Male; Mid | 1970 |